Arix Bioscience leads $45 million Series B financing round into LogicBio Therapeutics

Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed Series B financing round raising $45 million for LogicBio Therapeutics Inc. (“LogicBio”), a new Arix Group Business focused on breakthrough, disease-modifying gene therapies for orphan paediatric diseases.

The fundraising led by Arix Bioscience included new investors OrbiMed, Edmond De Rothschild Investment Partners, Pontifax, and SBI, along with previous investors OrbiMed Israel Partners. As part of the financing, Arix Bioscience’s Investment Manager, Daniel O’Connell, MD, PhD, will join LogicBio’s Board of Directors.

Read more